How much does a box of ritexitinib cost in China?

Ritlecitinib is an oral, highly selective Janus kinase (JAK) inhibitor. Preparations, mainly targeting JAK3 and TEC family kinases, for the treatment of alopecia areata (Alopecia Areata). Alopecia areata is an autoimmune disease characterized by the immune system attacking hair follicles, resulting in local or systemic hair loss. Ritexitinib reduces the attack of immune cells on hair follicles by inhibiting the JAK-STAT signaling pathway, thereby helping to protect hair follicles and promote hair regeneration.

In clinical trials, ritexitinib has shown significant efficacy in patients with moderate to severe alopecia areata, especially those who have responded poorly to other treatments. After 24 weeks of treatment, studies have shown significant improvements in hair coverage in many patients, and the drug is well tolerated. Common adverse reactions include upper respiratory tract infection, headache, gastrointestinal discomfort, etc. Most symptoms are mild to moderate.

Ritexitinib is currently on the market in China, providing a new treatment option for domestic patients with alopecia areata. Although the drug has not yet been included in the national medical insurance list, patients can still purchase it in domestic hospitals or regular pharmacies. The domestic price of ritexitinib is approximately more than 3,000 yuan per box. The specific selling price may vary depending on hospitals and regions. The dosage of each box is usually one month's supply, but patients need to purchase and use it according to the doctor's prescription and recommended treatment plan.

Since the price of ritexitinib is relatively high and it is not yet covered by medical insurance, patients should learn more about the treatment plan and medication cycle of the drug before purchasing it, and discuss the possible financial burden with their doctor. For some patients with greater financial pressure, they can consult local pharmacies or medical institutions to find out whether there are any assistance projects or preferential measures.

Despite its higher price, the launch of ritexitinib brings a new treatment option to patients with alopecia areata. Not only does it help patients restore their hair, it also significantly improves their quality of life. In the future, with the accumulation of more clinical data, ritixitinib is expected to further expand its application scope and bring more possibilities in medical insurance coverage.